SRPT Stock Risk & Deep Value Analysis
Sarepta Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SRPT Stock
We analyzed Sarepta Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SRPT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SRPT Risk Analysis & Red Flags
What Could Go Wrong
The company's primary gene therapy, Elevidys, continues to face significant commercialization challenges and skepticism regarding patient uptake and payer access. Should this commercial underperformance persist, leading to sustained revenue declines and wider losses, the company may require dilutive financing, significantly impacting shareholder value and long-term prospects.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Q4 2025 wider-than-expected loss and significant revenue decline (actuals not detailed but noted as 'weaker-than-expected')
- ⚠
Reduced 2026 net product revenue guidance ($1.2B-$1.4B vs $1.86B in 2025)
- ⚠
Persistent commercial execution challenges for Elevidys, as noted in previous analysis
- ⚠
Negative to neutral analyst sentiment with multiple 'Sell' or 'Underperform' ratings and price targets well below current stock price
- ⚠
Delayed siRNA data disclosure from H2 2025 to Q1 2026, with initial data limited to single ascending dose and no splicing data
Upcoming Risk Events
- 📅
Further negative revisions to 2026 revenue guidance
- 📅
Failure to achieve traditional approval for Amondys 45 and Vyondys 53
- 📅
Unfavorable results or delays in future siRNA clinical trials
- 📅
Increased competitive pressure in the DMD gene therapy market
When to Reconsider
- 🚪
Further downward revisions to 2026/2027 revenue guidance below current $1.2B-$1.4B range
- 🚪
Failure to receive traditional approval for Amondys 45 and Vyondys 53 in Q2 2026
- 🚪
Discontinuation or significant setback in key siRNA pipeline programs (SRP-1001, SRP-1003)
Unlock SRPT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Sarepta Therapeutics Inc (SRPT) Do?
Market Cap
$2.29B
Sector
Healthcare
Industry
Biotechnology
Employees
1,372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Visit Sarepta Therapeutics Inc WebsiteInvestment Thesis
Sarepta Therapeutics presents a high-risk, high-reward opportunity rooted in its pioneering gene and RNA therapy platforms targeting severe rare diseases like DMD. Despite significant commercial setbacks and negative financial trends with Elevidys, its robust pipeline, particularly the advancing siRNA programs, could unlock substantial long-term value. Investment hinges on improved commercial execution and successful progression of its next-generation therapies.
Is SRPT Stock Undervalued?
Unlock the full AI analysis for SRPT
Get the complete DVR score, risk analysis, and more
SRPT Price Targets & Strategy
12-Month Target
$18.00
Bull Case
$35.00
Bear Case
$8.00
Valuation Basis
Based on 1.4x FY26 Revenue guidance of $1.3B on an estimated 105M shares, reflecting current commercial headwinds and analyst skepticism.
Entry Strategy
Given current analyst targets significantly below current price, a cautious approach is warranted. Consider dollar-cost averaging on further dips towards the $15-$18 range if sentiment improves or clear operational stabilization emerges. Avoid aggressive entry until commercial execution visibly improves.
Exit Strategy
Take 50% profit if stock reaches $30 on positive pipeline news or commercial turnaround. Set a stop loss at $15 to limit downside risk if commercial outlook deteriorates further or major pipeline failures occur.
Portfolio Allocation
2% for aggressive risk tolerance due to significant execution risk and negative current financial trajectory.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is SRPT Financially Healthy?
Valuation
P/E Ratio
-2.59
Forward P/E
123.18
PEG Ratio
0.28
Profitability
Net Margin
-38.34%
Return on Equity
-50.74%
Revenue Growth
-32.70%
EPS
$-2.77
Balance Sheet
Current Ratio
2.32
Quick Ratio
1.48
Debt/Equity
0.73
Other
Beta (Volatility)
0.42
Does SRPT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
Sarepta's moat is currently eroding due to significant commercial execution challenges for its lead gene therapy, Elevidys, and intense competition in the rare disease space. While its IP provides a foundation, the ability to translate this into market leadership and sustained profitability is under pressure.
Moat Erosion Risks
- •Failure to achieve widespread patient uptake and payer access for approved therapies
- •Emergence of superior or more commercially successful competitive gene/RNA therapies
- •Loss of exclusivity or patent challenges for key pipeline assets
SRPT Competitive Moat Analysis
Sign up to see competitive advantages
SRPT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data, but mixed investor sentiment likely due to commercial challenges versus pipeline potential.
Institutional Sentiment
Negative - Analyst consensus includes 'Sell' and 'Market Perform' ratings, with price targets ($9-$15) significantly below the current price.
Insider Activity (Form 4)
Louise Rodino-Klapac (President, R&D and Tech Ops) had 948 shares withheld ($16,142) on March 11, 2026, for RSU tax obligations. Ian Michael Estepan (COO) had 1,097 shares withheld ($18,682) on March 11, 2026, for RSU tax obligations. No open market purchases or significant sales reported by CEO/CFO.
Options Flow
Normal options activity - No specific data available to indicate unusual institutional positioning.
Earnings Intelligence
Next Earnings
Not available
Surprise Probability
Medium - Given the significant Q4 2025 miss and reduced guidance, expectations are likely low, potentially increasing the chance for a positive surprise if commercial execution shows even slight improvement.
Historical Earnings Pattern
Stock has historically reacted negatively to commercial execution misses and downward guidance revisions, as seen with the Q4 2025 earnings report leading to a significant re-rating.
Key Metrics to Watch
Competitive Position
Top Competitor
Arrowhead Pharmaceuticals (ARWR) - as a partner/competitor in RNA therapies, though not directly in DMD gene therapy.
Market Share Trend
Losing ground or failing to capture expected share in the DMD gene therapy market due to commercial execution issues and payer access skepticism.
Valuation vs Peers
Likely trading at a premium to peers on long-term pipeline potential in gene/RNA therapy, but at a discount or significant discount on traditional profitability metrics (P/E, FCF yield) due to current losses and revenue decline.
Competitive Advantages
- •First-mover advantage and early approvals in DMD gene therapy (Elevidys)
- •Proprietary RNA-based therapeutic platforms and extensive rare disease pipeline
- •Established regulatory experience with multiple approved DMD products
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SRPT Stock Higher?
Near-Term (0-6 months)
- •Planned sNDA submission to FDA for traditional approval of Amondys 45 and Vyondys 53 (End of April 2026)
- •Q1 2026 Earnings Report (Date Not Available, but expected soon)
Medium-Term (6-18 months)
- •Additional (multiple ascending dose) clinical data from Phase 1/2 siRNA programs (SRP-1001, SRP-1003) (H2 2026)
- •Potential stabilization/improvement in Elevidys commercial ramp-up
Long-Term (18+ months)
- •Broader pipeline development and expansion of siRNA programs into additional indications
- •Establishment of long-term market leadership in gene/RNA therapies for rare diseases
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SRPT?
- ✓
Any indications of stabilizing or accelerating sales for Elevidys, alongside positive commentary on payer access
- ✓
Strong, comprehensive clinical data (e.g., splicing data for siRNA programs) from upcoming pipeline readouts
- ✓
Positive regulatory decisions for sNDA submissions or new drug applications
Bull Case Analysis
See what could go right with Premium
Competing with SRPT
See how Sarepta Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Sarepta Therapeutics Inc SRPT | $2.3B | 4.1 | -2.6 | $2.4B | -38.3% | -32.7% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Sarepta Therapeutics Inc Makes Money
Sarepta Therapeutics is a specialized biopharmaceutical company that focuses on developing and selling innovative gene and RNA-based treatments for devastating rare genetic diseases, primarily Duchenne muscular dystrophy (DMD). They make money by discovering new therapeutic candidates, rigorously testing them in clinical trials, securing regulatory approvals, and then selling these high-cost, specialized medications directly to patients through healthcare systems. Their goal is to provide life-changing treatments for conditions with limited options, relying on the success of their product launches and market penetration within these niche patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Sarepta Therapeutics Inc (SRPT)?
As of April 5, 2026, Sarepta Therapeutics Inc has a DVR Score of 4.1 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Sarepta Therapeutics Inc?
Sarepta Therapeutics Inc's market capitalization is approximately $2.3B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Sarepta Therapeutics Inc use?
SRPT is the ticker symbol for Sarepta Therapeutics Inc. The company trades on the NMS.
What is the risk level for SRPT stock?
Our analysis rates Sarepta Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SRPT?
Sarepta Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -2.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Sarepta Therapeutics Inc's revenue growing?
Sarepta Therapeutics Inc has reported revenue growth of -32.7%. Revenue has been declining, which warrants closer examination.
Is SRPT stock profitable?
Sarepta Therapeutics Inc has a profit margin of -38.3%. The company is currently unprofitable.
How often is the SRPT DVR analysis updated?
Our AI-powered analysis of Sarepta Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 5, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SRPT (Sarepta Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.